Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL402063 ((E)-Guggulsterone) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
Androgen receptor/Androgen Receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1871] [GtoPdb: 628] [UniProtKB: P10275] | ||||||||
ChEMBL | Inhibitory concentration against Androgen receptor | B | 6.62 | pKi | 240 | nM | Ki | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Inhibitory concentration against Androgen receptor | B | 6.66 | pIC50 | 220 | nM | IC50 | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
Farnesoid X receptor/Bile acid receptor FXR in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2047] [GtoPdb: 603] [UniProtKB: Q96RI1] | ||||||||
ChEMBL | Inhibitory concentration against Farnesoid X receptor | B | 5.3 | pKi | >5000 | nM | Ki | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Inhibitory concentration against Farnesoid X receptor; range from 50-100000 | B | 4 | pIC50 | 100000 | nM | IC50 | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Antagonist activity at human FXR expressed in CV-1 cells assessed as inhibition of CDCA-induced transactivation after 24 hrs by luciferase reporter gene assay | F | 4.36 | pIC50 | 44000 | nM | IC50 | J Nat Prod (2011) 74: 90-94 [PMID:21142112] |
ChEMBL | Antagonist activity at human FXR expressed in HEK293 cells assessed as inhibition of GW4064-induced transactivation after 24 hrs by luciferase reporter gene assay | B | 4.39 | pIC50 | 41000 | nM | IC50 | J Nat Prod (2016) 79: 499-506 [PMID:26821210] |
ChEMBL | Antagonist activity at GST-tagged FXR-LBD (unknown origin) assessed as inhibition of CDCA-induced biotinylated SRC-1 recruitment after 30 mins in presence of CDCA by Alpha Screen assay | B | 4.6 | pIC50 | 25000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Antagonist activity at human wild type FXR expressed in HEK293T cells co-transfected with reporter vector harboring human FXR-IR1 response element sequence after 18 hrs in presence of 0.5 uM FXR agonist, OCR by luciferase based reporter gene transactivation assay | B | 4.89 | pIC50 | 13000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Antagonist activity at human wild type FXR expressed in HEK293T cells co-transfected with reporter vector harboring human FXR-IR1 response element sequence after 18 hrs in presence of 1 uM FXR agonist, UPF-930 by luciferase based reporter gene transactivation assay | B | 5 | pIC50 | 10000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Antagonist activity at human FXR T396E mutant expressed in HEK293T cells co-transfected with reporter vector harboring human FXR-IR1 response element sequence after 18 hrs in presence of 0.5 uM FXR agonist, OCR by luciferase based reporter gene transactivation assay | B | 5.22 | pIC50 | 6000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Antagonist activity at human FXR T396E mutant expressed in HEK293T cells co-transfected with reporter vector harboring human FXR-IR1 response element sequence after 18 hrs in presence of 1 uM FXR agonist, UPF930 by luciferase based reporter gene transactivation assay | B | 5.38 | pIC50 | 4200 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Antagonist activity at human FXR expressed in monkey CV1 cells after 24 hrs by ecdysone receptor response element-driven luciferase reporter assay | F | 5.39 | pIC50 | 4100 | nM | IC50 | J Nat Prod (2007) 70: 1691-1695 [PMID:17988093] |
GtoPdb | - | - | 6 | pIC50 | 1000 | nM | IC50 | Mol Endocrinol (2002) 16: 1590-7 [PMID:12089353] |
ChEMBL | Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotinylated SRC-1 recruitment after 30 mins by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Noncompetitive antagonist activity at GST-tagged human FXR-LBD domain assessed as EC50 for OCA-induced biotinylated SRC-1 recruitment at 100 uM after 30 mins in presence of FXR agonist, OCA by Alpha Screen assay (Rvb = 0.2 uM) | B | 6.38 | pEC50 | 420 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Noncompetitive antagonist activity at GST-tagged human FXR-LBD domain assessed as EC50 for UPF930-induced biotinylated SRC-1 recruitment at 50 uM after 30 mins in presence of FXR agonist, UPF930 by Alpha Screen assay (Rvb = 0.14 uM) | B | 6.4 | pEC50 | 400 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Noncompetitive antagonist activity at GST-tagged human FXR-LBD domain assessed as EC50 for UPF930-induced biotinylated SRC-1 recruitment at 100 uM after 30 mins in presence of FXR agonist, UPF930 by Alpha Screen assay (Rvb = 0.14 uM) | B | 6.42 | pEC50 | 380 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Noncompetitive antagonist activity at GST-tagged human FXR-LBD domain assessed as EC50 for OCA-induced biotinylated SRC-1 recruitment at 50 uM after 30 mins in presence of FXR agonist, OCA by Alpha Screen assay (Rvb = 0.2 uM) | B | 6.51 | pEC50 | 310 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Noncompetitive antagonist activity at GST-tagged human FXR-LBD domain assessed as EC50 for OCA-induced biotinylated SRC-1 recruitment at 10 uM after 30 mins in presence of FXR agonist, OCA by Alpha Screen assay (Rvb = 0.2 uM) | B | 6.66 | pEC50 | 220 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Noncompetitive antagonist activity at GST-tagged human FXR-LBD domain assessed as EC50 for UPF930-induced biotinylated SRC-1 recruitment at 10 uM after 30 mins in presence of FXR agonist, UPF930 by Alpha Screen assay (Rvb = 0.14 uM) | B | 6.89 | pEC50 | 130 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Farnesoid X receptor in Mouse [GtoPdb: 603] [UniProtKB: Q3V1T8] | ||||||||
GtoPdb | - | - | 5 | pEC50 | - | - | - | Science (2002) 296: 1703-6 [PMID:11988537] |
Estrogen receptor-α/Estrogen receptor alpha in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL206] [GtoPdb: 620] [UniProtKB: P03372] | ||||||||
ChEMBL | Antagonist activity at ER (unknown origin) by Alpha Screen assay | B | 4.21 | pIC50 | 62000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at ER (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Glucocorticoid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2034] [GtoPdb: 625] [UniProtKB: P04150] | ||||||||
ChEMBL | Inhibitory concentration against Glucocorticoid receptor | B | 6.65 | pKi | 224 | nM | Ki | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Antagonist activity at GR (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Inhibitory concentration against Glucocorticoid receptor | B | 5.76 | pIC50 | 1740 | nM | IC50 | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Agonist activity at GR (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Liver X receptor-α/LXR-alpha in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2808] [GtoPdb: 602] [UniProtKB: Q13133] | ||||||||
ChEMBL | Antagonist activity at LXR alpha (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at LXR alpha (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Liver X receptor-β/LXR-beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4093] [GtoPdb: 601] [UniProtKB: P55055] | ||||||||
ChEMBL | Antagonist activity at LXR beta (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at LXR beta (unknown origin) by Alpha Screen assay | B | 5.44 | pEC50 | 3600 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Mineralocorticoid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1994] [GtoPdb: 626] [UniProtKB: P08235] | ||||||||
ChEMBL | Inhibitory concentration against Mineralocorticoid receptor | B | 7.41 | pKi | 39 | nM | Ki | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Inhibitory concentration against Mineralocorticoid receptor | B | 6 | pIC50 | 1000 | nM | IC50 | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Antagonist activity at MR (unknown origin) by Alpha Screen assay | B | 6.49 | pIC50 | 320 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at MR (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Peroxisome proliferator-activated receptor-α/Peroxisome proliferator-activated receptor alpha in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL239] [GtoPdb: 593] [UniProtKB: Q07869] | ||||||||
ChEMBL | Antagonist activity at PPARalpha (unknown origin) by Alpha Screen assay | B | 4.7 | pIC50 | 20000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at PPARalpha (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Peroxisome proliferator-activated receptor-β/δ/Peroxisome proliferator-activated receptor delta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3979] [GtoPdb: 594] [UniProtKB: Q03181] | ||||||||
ChEMBL | Antagonist activity at PPARdelta (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at PPARdelta (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Peroxisome proliferator-activated receptor-γ/Peroxisome proliferator-activated receptor gamma in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL235] [GtoPdb: 595] [UniProtKB: P37231] | ||||||||
ChEMBL | Antagonist activity at PPARgamma (unknown origin) by Alpha Screen assay | B | 4.57 | pIC50 | 27000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at PPARgamma (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Pregnane X receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3401] [GtoPdb: 606] [UniProtKB: O75469] | ||||||||
ChEMBL | Antagonist activity at PXR (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Inhibitory concentration against Pregnane X receptor | B | 8.62 | pIC50 | 2.4 | nM | IC50 | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Agonist activity at PXR (unknown origin) by Alpha Screen assay | B | 5.6 | pEC50 | 2500 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Progesterone receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL208] [GtoPdb: 627] [UniProtKB: P06401] | ||||||||
ChEMBL | Inhibitory concentration against Progesterone receptor | B | 6.7 | pKi | 201 | nM | Ki | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Antagonist activity at PR (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Inhibitory concentration against Progesterone receptor | B | 5.92 | pIC50 | 1200 | nM | IC50 | J Med Chem (2005) 48: 6948-6955 [PMID:16250653] |
ChEMBL | Agonist activity at PR (unknown origin) by Alpha Screen assay | B | 5.72 | pEC50 | 1900 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Retinoid X receptor-α/Retinoid X receptor alpha in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2061] [GtoPdb: 610] [UniProtKB: P19793] | ||||||||
ChEMBL | Antagonist activity at RXRalpha (unknown origin) by Alpha Screen assay | B | 4.48 | pIC50 | 33000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at RXRalpha (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Thyroid hormone receptor-α/Thyroid hormone receptor-β/Thyroid hormone receptor in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2111462] [GtoPdb: 588, 589] [UniProtKB: P10827, P10828] | ||||||||
ChEMBL | Antagonist activity at TR (unknown origin) by Alpha Screen assay | B | 4 | pIC50 | >100000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at TR (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
Vitamin D receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1977] [GtoPdb: 605] [UniProtKB: P11473] | ||||||||
ChEMBL | Antagonist activity at VDR (unknown origin) by Alpha Screen assay | B | 5.7 | pIC50 | 2000 | nM | IC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL | Agonist activity at VDR (unknown origin) by Alpha Screen assay | B | 4 | pEC50 | >100000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]